Citizen Bioscience: The Next Frontier?
The cure for a disease depends mostly on individual and hereditary biology, the markers across generations and behavior patterns. The more knowledge acquired, the greater the chances of finding better treatments for various diseases and their variants.
This blast from the past is biology’s next serious leap.
With more than 5 million users and a market value exceeding $2 billion, 23andMe boasts partners such as GlaxoSmithKline and Warren Buffett.
- An introduction to the concept of citizen bioscience and a brief discussion of the citizen science ecosystem that has gained momentum in the developing world during the last decade
- Showcase of current projects from around the world and assessment of the potential of multiple sub-sectors to answer the question: Is Citizen Bioscience the Next Frontier?
- Information on some active citizen bioscience projects and initiatives which have been remarkably successful in advancing scientific knowledge, and contributions from citizen scientists around the world
- Discussion of an initiative called Citizen Data Science, and growth prospects for citizen data scientists in the healthcare industry
The analyst of this report, Smruti Munshi, has specialized in the medical technologies space for more than five years. She focuses on monitoring and analyzing emerging trends, technologies, competitive benchmarking, and market dynamics in the medical imaging industry. She has worked on several projects spanning the EMEA markets, ranging from market insights, industry overviews, to comprehensive marketing and technology-oriented custom consulting. Ms. Munshi has an MS in Biomedical Engineering and a BS in Instrumentation and Control Engineering. She has authored several reports for BCC Research in the medical field.